AnaptysBio, a clinical-stage biotechnology company based in San Diego, focuses on immune cell modulators and has two checkpoint agonists in Phase 2 trials for autoimmune diseases. The company went public on January 26, 2017, and employs 117 staff.
AnaptysBio (ANAB) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, AnaptysBio's actual EPS was -$1.14, beating the estimate of -$1.68 per share, resulting in a 32.14% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
